Comunicados de Prensa de 2008
19 de deciembre de 2008
INTANZA® / IDflu®, first intradermal influenza vaccine recommended in the European Union
INTANZA® / IDflu®, first intradermal influenza vaccine recommended in the European Union
12 de noviembre de 2008
Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of All Infants
Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of All Infants
10 de noviembre de 2008
Sanofi Pasteur: Primera compañía internacional de vacunas que ingresa en Japón con una vacuna pediátrica
26 de octubre de 2008Sanofi Pasteur: Primera compañía internacional de vacunas que ingresa en Japón con una vacuna pediátrica
High-Dose Influenza Vaccine Shows Increased Immune Response Among Adults 65 Years of Age and Older25 de septiembre de 2008
Sanofi Pasteur finaliza la adquisición de Acambis
17 de Septiembre de 2008
Se estudiará un protocolo polivalente basado en la administración de una vacuna terapéutica contra el cáncer, para el tratamiento del melanoma
Se estudiará un protocolo polivalente basado en la administración de una vacuna terapéutica contra el cáncer, para el tratamiento del melanoma
September 2, 2008
Acambis' shareholders approve Sanofi Pasteur Holding's Offer by a large majority
Acambis' shareholders approve Sanofi Pasteur Holding's Offer by a large majority
August 1, 2008
Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
July 28, 2008Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
Recommeded Offer by Sanofi Pasteur for Acambis plcJune 25, 2008
Sanofi Pasteur Inaugurates High Tech Vaccine Production Facility to Respond to Soaring Demand WorldwideJune 23, 2008
U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, PentacelJune 17, 2008
Sanofi-aventis becomes a major partner in the biotechnology field in year leading to BIO 2008
With nine major agreements concluded in the last twelve months, sanofi-aventis is a partner of choice to develop molecules & vaccines for the futureJune 16, 2008
Sanofi Pasteur to donate 60 million doses of H5N1 vaccine to WHO over 3 years for its influenza vaccine global stockpile
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization (WHO) over 3 years for the establishment of an H5N1 vaccine global stockpile.April 28, 2008
U.S. Government accepts $192 million of sanofi pasteur H5N1 bulk vaccine antigen for pandemic stockpileApril 15, 2008
Sanofi Pasteur invests 100 million Canadian dollars in an R&D facility in Canada to boost innovation in vaccine research for global healthMarch 13, 2008
U.S. FDA Licenses DAPTACEL Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization SeriesFebruary 26, 2008
Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latina AmericaFebruary 14, 2008
Sanofi Pasteur and Statens Serum Institut Team Up Against TuberculosisFebruary 13, 2008
Sanofi Pasteur Files for European Approval of the First Seasonal Influenza Vaccine Delivered by Intradermal MicroinjectionJanuary 3, 2008
Sanofi Pasteur Enters Agreement with Crucell for Next-generation Biologicals against Rabies
Acceda directamente a las rúbricas:
